Natera, Inc. (NASDAQ:NTRA) Director Rowan E. Chapman Sells 2,614 Shares

Natera, Inc. (NASDAQ:NTRA) Director Rowan E. Chapman sold 2,614 shares of the firm’s stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $127.68, for a total transaction of $333,755.52. Following the completion of the transaction, the director now directly owns 7,969 shares in the company, valued at approximately $1,017,481.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Natera Trading Down 0.1 %

NASDAQ:NTRA opened at $127.10 on Thursday. The stock has a fifty day moving average price of $113.80 and a two-hundred day moving average price of $104.89. The stock has a market capitalization of $15.61 billion, a price-to-earnings ratio of -40.74 and a beta of 1.53. The company has a debt-to-equity ratio of 0.34, a quick ratio of 4.01 and a current ratio of 4.14. Natera, Inc. has a 1 year low of $36.90 and a 1 year high of $132.01.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Thursday, August 8th. The medical research company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.39. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The business had revenue of $413.35 million for the quarter, compared to analyst estimates of $343.00 million. During the same quarter last year, the company earned ($0.97) earnings per share. The business’s revenue for the quarter was up 58.1% compared to the same quarter last year. As a group, sell-side analysts anticipate that Natera, Inc. will post -1.96 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Natera

Hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. raised its holdings in shares of Natera by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 11,044,743 shares of the medical research company’s stock valued at $1,010,152,000 after buying an additional 72,848 shares during the period. Farallon Capital Management LLC boosted its position in Natera by 13.6% during the 2nd quarter. Farallon Capital Management LLC now owns 4,460,557 shares of the medical research company’s stock worth $483,034,000 after acquiring an additional 532,874 shares during the period. Massachusetts Financial Services Co. MA boosted its position in Natera by 6.6% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 2,397,582 shares of the medical research company’s stock worth $259,634,000 after acquiring an additional 148,917 shares during the period. Duquesne Family Office LLC boosted its position in Natera by 2.4% during the 2nd quarter. Duquesne Family Office LLC now owns 1,974,880 shares of the medical research company’s stock worth $213,860,000 after acquiring an additional 45,500 shares during the period. Finally, Norges Bank acquired a new position in Natera during the 4th quarter worth $83,970,000. 99.90% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. UBS Group lowered their target price on shares of Natera from $160.00 to $145.00 and set a “buy” rating on the stock in a report on Friday, August 9th. Jefferies Financial Group assumed coverage on shares of Natera in a research note on Monday, June 3rd. They issued a “buy” rating and a $142.00 price target on the stock. StockNews.com downgraded shares of Natera from a “hold” rating to a “sell” rating in a research note on Wednesday, August 28th. Morgan Stanley increased their target price on shares of Natera from $125.00 to $132.00 and gave the stock an “overweight” rating in a report on Tuesday, August 13th. Finally, Stephens restated an “overweight” rating and issued a $125.00 price target on shares of Natera in a report on Friday, August 9th. One equities research analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $120.07.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.